NCT01286896 2025-07-10
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The Netherlands Cancer Institute
Phase 1 Completed
Clinical Trials
14 trialsNCT01023737 2023-02-13
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 1 Completed
NCT02923466 2022-04-27
Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors
Vyriad, Inc.
Phase 1 Completed
NCT01337505 2022-02-10
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
NCT02857920 2020-09-14
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT02843204 2020-05-28
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
Fuda Cancer Hospital, Guangzhou
Phase 1/2 Completed
NCT01435096 2020-03-03
BN80927 in Patients With Advanced Malignant Solid Tumors
Ipsen
Phase 1 Completed
NCT02853903 2019-09-12
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
Fuda Cancer Hospital, Guangzhou
Phase 2 Completed
NCT01721148 2017-01-25
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
ASLAN Pharmaceuticals
Phase 1 Completed
NCT01611857 2016-11-23
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00388427 2015-05-28
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
University of Pittsburgh
Phase 1 Completed
NCT01343498 2015-05-01
Study of PI3 Kinase/mTOR Inhibitor BEZ235 Twice Daily for Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT01184807 2014-03-26
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
Otsuka Beijing Research Institute
Phase 1 Completed
NCT01951846 2013-09-27
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
Boehringer Ingelheim
Phase 1 Completed